The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients

Detalles Bibliográficos
Autores principales: Stellbrink, HJ, Rugina, S, Zagler, C, Esser, S, Castagna, A, Gazzard, B, Hill, A, van Delft, Y, Marks, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The International AIDS Society 2010
Materias:
Oral Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112862/
http://dx.doi.org/10.1186/1758-2652-13-S4-O47
_version_ 1782205834371006464
author Stellbrink, HJ
Rugina, S
Zagler, C
Esser, S
Castagna, A
Gazzard, B
Hill, A
van Delft, Y
Marks, S
author_facet Stellbrink, HJ
Rugina, S
Zagler, C
Esser, S
Castagna, A
Gazzard, B
Hill, A
van Delft, Y
Marks, S
author_sort Stellbrink, HJ
collection PubMed
description
format Online
Article
Text
id pubmed-3112862
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher The International AIDS Society
record_format MEDLINE/PubMed
spelling pubmed-31128622011-06-13 The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients Stellbrink, HJ Rugina, S Zagler, C Esser, S Castagna, A Gazzard, B Hill, A van Delft, Y Marks, S J Int AIDS Soc Oral Presentation The International AIDS Society 2010-11-08 /pmc/articles/PMC3112862/ http://dx.doi.org/10.1186/1758-2652-13-S4-O47 Text en Copyright ©2010 Stellbrink et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Oral Presentation
Stellbrink, HJ
Rugina, S
Zagler, C
Esser, S
Castagna, A
Gazzard, B
Hill, A
van Delft, Y
Marks, S
The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
title The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
title_full The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
title_fullStr The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
title_full_unstemmed The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
title_short The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
title_sort sense trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
topic Oral Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112862/
http://dx.doi.org/10.1186/1758-2652-13-S4-O47
work_keys_str_mv AT stellbrinkhj thesensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT ruginas thesensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT zaglerc thesensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT essers thesensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT castagnaa thesensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT gazzardb thesensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT hilla thesensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT vandelfty thesensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT markss thesensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT stellbrinkhj sensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT ruginas sensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT zaglerc sensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT essers sensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT castagnaa sensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT gazzardb sensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT hilla sensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT vandelfty sensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients
AT markss sensetrialetravirineshowslowerprevalenceandseverityofneuropsychiatricadverseeventscomparedtoefavirenzintreatmentnaivepatients

Ejemplares similares